INS and fatty liver disease: Next, we investigated whether celecoxib affected the aforementioned lipogenic targets in the livers of fructose‐fed mice, a preclinical non‐alcoholic fatty liver model featuring enhanced de novo lipogenesis stimulated in an insulin/Akt‐independent manner.13